|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||15.77 - 16.51|
|52 Week Range||15.77 - 30.35|
|Beta (3Y Monthly)||2.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.67|
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
TUCSON, Ariz. , Sept. 27, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that Joan Martin resigned from his position as Executive Vice President and Head of Europe , Middle East , and ...
NEW YORK, Aug. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CMS ...
TUCSON, Ariz., Aug. 7, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that it received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the United States. The contract was based on a recommendation of the Accelerate Pheno™ system by hospital experts in this category who serve on one of Vizient's member-led councils. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization's care delivery and business model. "We're honored that our technology was awarded this Innovative Technology contract, enabling it to be on contract without waiting for the next competitive bid cycle," said Marilyn Drake, Director of Corporate Business for Accelerate Diagnostics.
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -16.22% and -22.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Tucson, Arizona-based company said it had a loss of 43 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Revenue up 142 Percent, Global install base up 25 Percent TUCSON, Ariz. , Aug. 6, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending June 30 , 2018. ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:15 PM Eastern ...
Short interest is high for AXDX with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. Over the last one-month, outflows of investor capital in ETFs holding AXDX totaled $572 million.
Accelerate Diagnostics, Inc. announced today it will host a conference call on Monday, August 6, 2018 to review the company’s second quarter 2018 financial results and commercial progress. President and Chief Executive Officer, Lawrence Mehren, joined by Steve Reichling, Chief Financial Officer, will review financial results at 4:15 p.m. ET. Listen to an audio webcast of the call by visiting the events section of the company’s investor relations website at ir.axdx.com.
Accelerate Diagnostics Inc’s (NASDAQ:AXDX): Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. The US$1.30b market-cap posted a lossRead More...
On a per-share basis, the Tucson, Arizona-based company said it had a loss of 37 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...